A carregar...
Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress
The ability of the Cav1 channel inhibitor isradipine to slow the loss of substantia nigra pars compacta (SNc) dopaminergic (DA) neurons and the progression of Parkinson’s disease (PD) is being tested in a phase 3 human clinical trial. But it is unclear whether and how chronic isradipine treatment wi...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983329/ https://ncbi.nlm.nih.gov/pubmed/29708514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI95898 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|